Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2014 01:06 ET | Source: Ablynx

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, July 18, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree...
July 15, 2014 01:06 ET | Source: Ablynx

EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX

REGULATED INFORMATION GHENT, Belgium, July 15, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that Euronext N.V. will introduce Spotlight Options on the shares of...
July 08, 2014 12:24 ET | Source: Ablynx

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GHENT, Belgium, July 8, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major...
July 03, 2014 12:07 ET | Source: Ablynx

PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GHENT, Belgium, July 3, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO") took place today and as a...
June 30, 2014 16:41 ET | Source: Ablynx

ABLYNX SUCCESSFULLY RAISES EU41.7 MILLION

REGULATED INFORMATION GHENT, Belgium, June 30, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announces that it has raised €41,720,822 through a private placement of new...
June 20, 2014 01:04 ET | Source: Ablynx

ABLYNX WINS TRANSACTION OF THE YEAR AT THE 2014 EUROPEAN MEDISCIENCE AWARDS

GHENT, Belgium, June 20, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that at the European Mediscience Awards 2014, the Company won the Transaction of the Year Award for...
June 19, 2014 01:07 ET | Source: Ablynx

ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT DATA FOR ANTI-KV1.3 NANOBODIES AT TWO LEADING ION CHANNEL MEETINGS

GHENT, Belgium, June 19, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present pre-clinical proof-of-concept data on its proprietary anti-Kv1.3 Nanobody®...
June 17, 2014 01:07 ET | Source: Ablynx

ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, ACHIEVES CLINICAL PROOF-OF-CONCEPT IN PHASE II TITAN STUDY

First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura Proof-of-concept with statistically significant 39% decrease in time to...
June 10, 2014 01:07 ET | Source: Ablynx

ABLYNX TO PRESENT ADDITIONAL DATA ON ALX-0061, THE ANTI-IL-6R NANOBODY BEING DEVELOPED IN PARTNERSHIP WITH ABBVIE, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

GHENT, Belgium, June 10, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present additional positive data on its anti-IL-6R Nanobody®, ALX-0061, at the...
May 27, 2014 12:07 ET | Source: Ablynx

ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE

GHENT, Belgium, May 27, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announces it will present at the annual Jefferies 2014 Global Healthcare Conference at the Grand Hyatt in New...